

Matthew T Roe

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4334602/matthew-t-roe-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

228 papers	11,846 citations	54 h-index	102 g-index
238 ext. papers	13,993 ext. citations	7.7 avg, IF	5.74 L-index

#	Paper	IF	Citations
228	The National Cardiovascular Data Registry Data Quality Program 2020: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1704-1712	15.1	1
227	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021 , 384, 1981-1990	59.2	37
226	Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials. <i>Health and Quality of Life Outcomes</i> , 2021 , 19, 164	3	4
225	Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments. <i>Drugs</i> , 2021 , 81, 1235-1237	12.1	
224	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 33-43	3.9	10
223	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021 , 144, 1295-1307	16.7	13
222	Comparative Efficacy and Safety of Oral P2Y Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. <i>Circulation</i> , 2020 , 142, 150-160	16.7	44
221	Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX. <i>American Journal of Medicine</i> , 2020 , 133, e716-e721	2.4	4
220	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. <i>Circulation</i> , 2020 , 141, 1608-1617	16.7	52
219	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 162-171	15.1	17
218	Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. <i>American Journal of Cardiology</i> , 2020 , 125, 1280-1283	3	0
217	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. <i>Circulation</i> , 2020 , 141, 843-862	16.7	25
216	Targeting Vascular Calcification in Chronic Kidney Disease. <i>JACC Basic To Translational Science</i> , 2020 , 5, 398-412	8.7	35
215	Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements. <i>Scientific Reports</i> , 2020 , 10, 6169	4.9	8
214	Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design. <i>JACC: CardioOncology</i> , 2020 , 2, 70-81	3.8	15
213	Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout. <i>American Journal of Cardiology</i> , 2020 , 127, 64-72	3	5
212	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. <i>American Journal of Kidney Diseases</i> , 2020 , 76, 842-850	7.4	2

211	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 133-144	15.1	147
210	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020 , 41, 2248-2258	9.5	29
209	Leveraging electronic health record data for pragmatic randomized trials. <i>Clinical Trials</i> , 2020 , 17, 368-369		
208	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006582	5.8	2
207	Androgen deprivation therapy and cardiovascular disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 45-52	2.8	11
206	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1177-1186	15.1	33
205	Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome. <i>Physiological Genomics</i> , 2019 , 51, 506-515	3.6	2
204	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019 , 218, 110-122	4.9	7
203	Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). <i>American Journal of Cardiology</i> , 2019 , 123, 1193-1201	3	4
202	Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2019 , 214, 184-193	4.9	5
201	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019 , 4, 680-684	16.2	7
200	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019 , 140, 103-112	16.7	72
199	Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health. <i>Clinical Trials</i> , 2019 , 16, 419-430	2.2	7
198	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1167-1176	15.1	87
197	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 618-628	18.1	120
196	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005858	5.8	13
195	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019 , 140, 2054-2062	16.7	41
194	Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2019 , 381, 2479-2480	59.2	0

193	Seasonal and circadian patterns of myocardial infarction by coronary artery disease status and sex in the ACTION Registry-GWTG. <i>International Journal of Cardiology</i> , 2019 , 274, 16-20	3.2	9
192	Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention. <i>Circulation</i> , 2019 , 139, 458-472	16.7	20
191	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019 , 139, 863-873	16.7	8
190	Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 430-437	3.8	3
189	Association of acute myocardial infarction cardiac arrest patient volume and in-hospital mortality in the United States: Insights from the National Cardiovascular Data Registry Acute Coronary Treatment And Intervention Outcomes Network Registry. <i>Clinical Cardiology</i> , 2019 , 42, 352-357	3.3	9
188	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005041	5.8	8
187	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 387-396	15.1	96
186	Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial. <i>Coronary Artery Disease</i> , 2018 , 29, 469-476	1.4	3
185	Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018 , 4, 43-50	4.6	7
184	Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. <i>European Heart Journal</i> , 2018 , 39, 193-200	9.5	3
183	Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). <i>American Journal of Cardiology</i> , 2018 , 122, 1322-1329	3	2
182	Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. <i>American Journal of Cardiology</i> , 2018 , 122, 1451-1458	3	1
181	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. <i>American Heart Journal</i> , 2018 , 201, 25-32	4.9	6
180	Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2680-2690	15.1	89
179	Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program. <i>American Heart Journal</i> , 2018 , 197, 9-17	4.9	0
178	Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004755	5.8	23
177	The impact of clinical vs administrative claims coding on hospital risk-adjusted outcomes. <i>Clinical Cardiology</i> , 2018 , 41, 1225-1231	3.3	3
176	Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11, e004054	5.8	16

175	Long-Term Mortality of Older Patients With Acute Myocardial Infarction Treated in US Clinical Practice. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	26
174	Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	5
173	What is the best ST-segment recovery parameter to predict clinical outcome and myocardial infarct size? Amplitude, speed, and completeness of ST-segment recovery after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>Journal of Electrocardiology</i> , 2017 , 50, 952-959	1.4	2
172	Whole blood sequencing reveals circulating microRNA associations with high-risk traits in non-ST-segment elevation acute coronary syndrome. <i>Atherosclerosis</i> , 2017 , 261, 19-25	3.1	21
171	Longitudinal Risk of Adverse Events in Patients With Acute Kidney Injury After Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	39
170	Rejoinder. <i>Clinical Trials</i> , 2017 , 14, 126-127	2.2	
169	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017 , 63, 1214-1226	5.5	8
168	Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2913-2924	15.1	60
167	Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. <i>Clinical Cardiology</i> , 2017 , 40, 899-906	3.3	2
166	Data monitoring committees: Promoting best practices to address emerging challenges. <i>Clinical Trials</i> , 2017 , 14, 115-123	2.2	41
165	One and done: Reasons principal investigators conduct only one FDA-regulated drug trial. <i>Contemporary Clinical Trials Communications</i> , 2017 , 6, 31-38	1.8	15
164	Assessment of Operator Variability in Risk-Standardized Mortality Following Percutaneous Coronary Intervention: A Report From the NCDR. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 672-682	5	13
163	Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites With Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2017 , 119, 1127-1134	3	13
162	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. <i>Heart</i> , 2017 , 103, 1168-1176	5.1	25
161	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017 , 187, 194-203	4.9	15
160	Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. <i>American Heart Journal</i> , 2017 , 188, 156-166	4.9	8
159	Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. <i>International Journal of Cardiology</i> , 2017 , 241, 87-96	3.2	16
158	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet, The</i> , 2017 , 389, 1799-1808	40	132

157	Potent P2Y Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1549-1559	15.1	36
156	Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 445-458	3.9	6
155	Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10, e003443	5.8	9
154	Mortality of Myocardial Infarction by Sex, Age, and Obstructive Coronary Artery Disease Status in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017 , 10, e003443	5.8	145
153	Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 443-454	4.3	31
152	Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 443-454	4.3	79
151	US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1223-9	4.9	41
150	Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	2
149	A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. <i>American Heart Journal</i> , 2016 , 181, 92-100	4.9	17
148	The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 1898-1907	15.1	53
147	The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China. <i>American Heart Journal</i> , 2016 , 175, 193-201.e3	4.9	67
146	Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1289-97	15.1	13
145	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016 , 1, 73-9	16.2	13
144	Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 240-9		126
143	A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. <i>American Heart Journal</i> , 2016 , 174, 120-8	4.9	22
142	Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 936-947	15.1	32
141	Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial. <i>Stroke</i> , 2016 , 47, 1135-9	6.7	7
140	Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. <i>American Heart Journal</i> , 2016 , 174, 60-7	4.9	3

139	Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2016 , 176, 1-9	4.9	10
138	Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. <i>European Heart Journal</i> , 2016 , 37, 412-22	9.5	15
137	Indications, algorithms, and outcomes for coronary artery bypass surgery in patients with acute coronary syndromes. <i>Coronary Artery Disease</i> , 2016 , 27, 319-26	1.4	8
136	Excess of Solid Cancers After Prasugrel: The Food and Drug Administration Outlook. <i>American Journal of Therapeutics</i> , 2016 , 23, e243-4	1	4
135	Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. <i>Journal of the American Heart Association</i> , 2016 , 5, e002784	6	3
134	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. <i>Heart</i> , 2016 , 102, 1221-9	5.1	2
133	Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data Registry's CathPCI Registry. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e003070	6	25
132	Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. <i>Drug Safety</i> , 2016 , 39, 715-27	5.1	8
131	Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>American Heart Journal</i> , 2016 , 178, 55-64	4.9	2
130	Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention: An Instrumental Variable Analysis. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9, e003464	6	22
129	The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry CathPCI Registry. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 771-779	5	12
128	Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network CathPCI Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016 , 9, e003464	5.8	33
127	Differences in Short- and Long-Term Outcomes Among Older Patients With ST-Elevation Versus Non-ST-Elevation Myocardial Infarction With Angiographically Proven Coronary Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016 , 9, 513-22	5.8	23
126	Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. <i>Clinical Cardiology</i> , 2016 , 39, 497-506	3.3	4
125	Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. <i>Clinical Cardiology</i> , 2016 , 39, 329-37	3.3	5
124	The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015 , 169, 743-50	4.9	14
123	Gaps in referral to cardiac rehabilitation of patients undergoing percutaneous coronary intervention in the United States. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2079-88	15.1	92
122	Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the Targeted platelet Inhibition to clarify the Optimal strategy to medically manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015 , 170, 695-705.e5	4.9	15

121	Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2015 , 169, 515-22.e1	4.9	28
120	Nationwide Analysis of Patients With ST-Segment-Elevation Myocardial Infarction Transferred for Primary Percutaneous Intervention: Findings From the American Heart Association Mission: Lifeline Program. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8,	6	41
119	Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry). <i>American Journal of Cardiology</i> , 2015 , 115, 1655-60	3	7
118	Time to treatment as a quality metric for acute STEMI care. <i>Lancet, The</i> , 2015 , 385, 1056-7	4.0	9
117	Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. <i>American Heart Journal</i> , 2015 , 170, 683-694.e3	4.9	22
116	Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. <i>Journal of the American Heart Association</i> , 2015 , 4, e001512	6	12
115	The Contemporary Use of Angiography and Revascularization Among Patients With Non-ST-Segment Elevation Myocardial Infarction in the United States Compared With South Korea. <i>Clinical Cardiology</i> , 2015 , 38, 708-14	3.3	7
114	The Association of Transfer Rate From Hospitals Without Revascularization Capabilities and Mortality Risk for Older Non-ST-Segment Elevation Myocardial Infarction Patients. <i>Clinical Cardiology</i> , 2015 , 38, 733-9	3.3	3
113	Direct Transfer From the Referring Hospitals to the Catheterization Laboratory to Minimize Reperfusion Delays for Primary Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002477	6	17
112	Cumulative incidence of death and rehospitalization among the elderly in the first year after NSTEMI. <i>American Journal of Medicine</i> , 2015 , 128, 582-90	2.4	23
111	Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry. <i>JAMA Internal Medicine</i> , 2015 , 175, 207-15	11.5	56
110	Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	41
109	The association of in-hospital guideline adherence and longitudinal postdischarge mortality in older patients with non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2015 , 170, 273-280.e1	4.9	15
108	Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2015 , 169, 257-265.e1	4.9	28
107	Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. <i>European Heart Journal</i> , 2015 , 36, 385-92a	9.5	28
106	Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. <i>Heart</i> , 2015 , 101, 279-86	5.1	9
105	Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 112-25	3.3	
104	Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. <i>American Heart Journal</i> , 2014 , 168, 76-87.e1	4.9	19

103	Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. <i>European Heart Journal</i> , 2014 , 35, 2516-23	9.5	65
102	Influence of presenting electrocardiographic findings on the treatment and outcomes of patients with non-ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2014 , 113, 256-61 ³		12
101	Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 701-7	5.8	24
100	Acute coronary syndromes: Treatment for low-risk patients with STEMI--challenges remain. <i>Nature Reviews Cardiology</i> , 2014 , 11, 440-2	14.8	
99	Do patients treated at academic hospitals have better longitudinal outcomes after admission for non-ST-elevation myocardial infarction?. <i>American Heart Journal</i> , 2014 , 167, 762-9	4.9	16
98	Predictors of reperfusion delay in patients with ST elevation myocardial infarction self-transported to the hospital (from the American Heart Association's Mission: Lifeline Program). <i>American Journal of Cardiology</i> , 2014 , 113, 798-802	3	13
97	Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR). <i>American Journal of Cardiology</i> , 2014 , 114, 1136-44	3	28
96	Characteristics and outcomes in patients undergoing percutaneous coronary intervention following cardiac arrest (from the NCDR). <i>American Journal of Cardiology</i> , 2014 , 113, 1087-92	3	25
95	Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease. <i>American Heart Journal</i> , 2014 , 167, 355-362.e3	4.9	6
94	Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. <i>American Heart Journal</i> , 2014 , 167, 840-5	4.9	12
93	Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. <i>American Heart Journal</i> , 2014 , 168, 503-511.e2	4.9	15
92	Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. <i>Journal of the American Heart Association</i> , 2014 , 3, e000849	6	75
91	In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. <i>Circulation: Cardiovascular Interventions</i> , 2014 , 7, 585-93	6	43
90	Differences in short-term versus long-term outcomes of older black versus white patients with myocardial infarction: findings from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of American College of Cardiology/American Heart Association Guideline (CANRISK-5). <i>Circulation</i> , 2014 , 130, 659-67	16.7	17
89	Association of body mass index and long-term outcomes in older patients with non-ST-segment-elevation myocardial infarction: results from the CRUSADE Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 102-9	5.8	27
88	Relationship of the distance between non-PCI hospitals and primary PCI centers, mode of transport, and reperfusion time among ground and air interhospital transfers using NCDR's ACTION Registry-GWTG: a report from the American Heart Association Mission: Lifeline Program. <i>Circulation: Cardiovascular Interventions</i> , 2014 , 7, 797-805	6	14
87	Independent data monitoring committees: preparing a path for the future. <i>American Heart Journal</i> , 2014 , 168, 135-41.e1	4.9	14
86	Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2014 , 167, 267-273.e1	4.9	9

85	Characteristics, management, and outcomes of cocaine-positive patients with acute coronary syndrome (from the National Cardiovascular Data Registry). <i>American Journal of Cardiology</i> , 2014 , 113, 749-56	3	29
84	Trends in outcomes among older patients with non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2014 , 167, 36-42.e1	4.9	8
83	Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. <i>American Heart Journal</i> , 2013 , 166, 864-70	4.9	36
82	Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. <i>Lancet, The</i> , 2013 , 382, 605-13	4.0	87
81	The association between smoking and long-term outcomes after non-ST-segment elevation myocardial infarction in older patients. <i>American Heart Journal</i> , 2013 , 166, 1056-62	4.9	18
80	Cardiovascular care facts: a report from the national cardiovascular data registry: 2011. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1931-1947	15.1	112
79	Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). <i>American Journal of Cardiology</i> , 2013 , 112, 1057-62	3	13
78	Long-term outcomes among older patients with non-ST-segment elevation myocardial infarction complicated by cardiogenic shock. <i>American Heart Journal</i> , 2013 , 166, 298-305	4.9	16
77	Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches. <i>American Heart Journal</i> , 2013 , 165, 644-54, 654.e1	4.9	8
76	Comparison of long-term outcomes between older Asian and white patients with non-ST-segment elevation myocardial infarction: findings from CRUSADE-CMS database. <i>American Heart Journal</i> , 2013 , 166, 1050-5	4.9	5
75	Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction. <i>American Heart Journal</i> , 2013 , 165, 43-9	4.9	16
74	Long-term outcomes after invasive management for older patients with non-ST-segment elevation myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013 , 6, 323-32	5.8	12
73	Emergency department bypass for ST-Segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program. <i>Circulation</i> , 2013 , 128, 352-9	16.7	76
72	Association of early physician follow-up and 30-day readmission after non-ST-segment-elevation myocardial infarction among older patients. <i>Circulation</i> , 2013 , 128, 1206-13	16.7	39
71	Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. <i>Circulation</i> , 2013 , 128, 823-33	16.7	103
70	Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1785-94	27.4	176
69	Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 12-20	7	6
68	Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. <i>American Heart Journal</i> , 2012 , 163, 720-8	4.9	40

67	The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2012 , 163, 705-13	4.9	18
66	Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2012 , 164, 502-8	4.9	5
65	Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1861-9	15.1	109
64	A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2017-31	15.1	213
63	Comparison of the prognostic value of peak creatine kinase-MB and troponin levels among patients with acute myocardial infarction: a report from the Acute Coronary Treatment and Intervention Outcomes Network Registry-get with the guidelines. <i>Clinical Cardiology</i> , 2012 , 35, 424-9	3.3	39
62	Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. <i>New England Journal of Medicine</i> , 2012 , 367, 1297-309	59.2	631
61	Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 594-600	5.8	39
60	Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 205-13	5.8	34
59	Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 541-9	5.8	51
58	The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2012 , 33, 2044-53	9.5	61
57	Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). <i>Journal of the American College of Cardiology</i> , 2011 , 58, 2642-50	15.1	159
56	Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: the CRUSADE long-term mortality model and risk score. <i>American Heart Journal</i> , 2011 , 162, 875-883.e1	4.9	70
55	In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry-GWTG. <i>American Journal of Cardiology</i> , 2011 , 107, 1136-43	3	171
54	Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality model and risk score. <i>American Heart Journal</i> , 2011 , 161, 1112-1122.e2	4.9	127
53	Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 1461-7	27.4	71
52	Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1923-32	15.1	319
51	Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 254-63	15.1	311
50	Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. <i>American Heart Journal</i> , 2010 , 159, 757-63	4.9	76

49	Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. <i>American Heart Journal</i> , 2010 , 160, 16-22.e1	4.9	109
48	Public sensationalism and clinical trials: how to address the challenges of science?. <i>American Journal of Medicine</i> , 2010 , 123, 481-3	2.4	7
47	Careers for clinician investigators. <i>Circulation</i> , 2009 , 119, 2945-50	16.7	8
46	A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009 , 2, 491-9	5.8	166
45	Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina patients supress ADverse outcomes with early implementation of the ACC/AHA guidelines (CRUSADE) and acute coronary treatment and	5.8	38
44	Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. <i>Circulation</i> , 2009 , 119, 3110-7	16.7	141
43	Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. <i>Circulation</i> , 2009 , 119, 1873-82	16.7	701
42	Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-ST-elevation acute coronary syndrome. <i>American Journal of Cardiology</i> , 2009 , 104, 1324-9	3	6
41	Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care. <i>Clinical Cardiology</i> , 2009 , 32, 519-25	3.3	2
40	Blood pressure paradox in patients with non-ST-segment elevation acute coronary syndromes: results from 139,194 patients in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative	4.9	7
39	The paradoxical use of cardiac catheterization in patients with non-ST-elevation acute coronary syndromes: lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC /AHA Guidelines (CRUSADE) Quality Improvement Initiative. <i>American Heart Journal</i> , 2009 , 158, 263-70	4.9	43
38	Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative. <i>American Heart Journal</i> , 2009 , 158, 748-754.e1	4.9	45
37	Factors associated with off-label use of drug-eluting stents in patients with ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2008 , 101, 286-92	3	13
36	Obesity and age of first non-ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 979-85	15.1	110
35	Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. <i>American Heart Journal</i> , 2008 , 155, 140-6	4.9	93
34	Noninvasive, medical management for non-ST-elevation acute coronary syndromes. <i>American Heart Journal</i> , 2008 , 155, 397-407	4.9	18
33	Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals. <i>American Heart Journal</i> , 2008 , 156, 185-92	4.9	41
32	Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). <i>American Heart Journal</i> , 2008 , 156, 606-12	4.9	27

31	Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2008 , 29, 2480-8	9.5	27
30	Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. <i>Circulation</i> , 2008 , 117, 886-96	16.7	176
29	Continuum of care in the treatment of ST-segment elevation myocardial infarction (STEMI): importance of platelet and coagulation inhibition. <i>Postgraduate Medicine</i> , 2008 , 120, 67-78	3.7	
28	Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. <i>JACC: Cardiovascular Interventions</i> , 2008 , 1, 369-78	5	42
27	Insurance Coverage and Care of Patients with NonST-Segment Elevation Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2007 , 147, 212	8	
26	Guideline Implementation Research: Exploring the Gap between Evidence and Practice in the CRUSADE Quality Improvement Initiative. <i>Academic Emergency Medicine</i> , 2007 , 14, 949-954	3.4	30
25	Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (From the CRUSADE Quality Improvement Initiative). <i>American Journal of Cardiology</i> , 2007 , 99, 1222-6	3	35
24	Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). <i>American Journal of Cardiology</i> , 2007 , 99, 1389-93	3	21
23	Development of systems of care for ST-elevation myocardial infarction patients: gaps, barriers, and implications. <i>Circulation</i> , 2007 , 116, e68-72	16.7	44
22	Pay for performance, quality of care, and outcomes in acute myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 2373-80	27.4	205
21	Influence of inpatient service specialty on care processes and outcomes for patients with non ST-segment elevation acute coronary syndromes. <i>Circulation</i> , 2007 , 116, 1153-61	16.7	35
20	Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2007 , 153, 507-14	4.9	41
19	Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. <i>Canadian Journal of Cardiology</i> , 2007 , 23, 1073-9	3.8	30
18	Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. <i>American Journal of Cardiology</i> , 2006 , 97, 1707-12	3	41
17	Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. <i>American Journal of Cardiology</i> , 2006 , 98, 624-7	3	37
16	Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). <i>American Journal of Cardiology</i> , 2006 , 98, 1172-6	3	39
15	Association between hospital process performance and outcomes among patients with acute coronary syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1912-20	27.4	458
14	Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. <i>Archives of Internal Medicine</i> , 2006 , 166, 2027-34		130

13	The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. <i>American Heart Journal</i> , 2006 , 151, 1205-13	4.9	100
12	Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1479-87	15.1	253
11	Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes. <i>Archives of Internal Medicine</i> , 2005 , 165, 1870-6		32
10	Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. <i>American Journal of Cardiology</i> , 2005 , 96, 750-5	3	54
9	Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. <i>Archives of Internal Medicine</i> , 2005 , 165, 1630-6		107
8	Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 3108-16	27.4	498
7	Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 2096-104	27.4	412
6	Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. <i>Journal of the American College of Cardiology</i> , 2003 , 42, 45-53	15.1	109
5	Changing the model of care for patients with acute coronary syndromes. <i>American Heart Journal</i> , 2003 , 146, 605-12	4.9	51
4	Improving the Care of Patients with Non-ST-elevation Acute Coronary Syndromes in the Emergency Department: The CRUSADE Initiative. <i>Academic Emergency Medicine</i> , 2002 , 9, 1146-1155	3.4	70
3	Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. <i>Academic Emergency Medicine</i> , 2002 , 9, 1146-55	3.4	113
2	Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 9-18	15.1	201
1	Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. <i>Circulation</i> , 2000 , 102, 1101-6	16.7	154